Aisling Capital Management LP
13F Reported Value
ⓘ$476.3M
Holdings
13
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Aisling Capital Management LP disclosed 13 positions worth $476.3M in its Form 13F-HR for Q1 2026, led by $BBIO (BridgeBio Pharma, Inc.) at 79.3% of the equity portfolio, followed by $SNDX and $GLUE. During the quarter the fund opened 1 new position and exited 1 — including a new stake in $EPRX and a full exit from $CALC. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Aisling Capital Management LP’s Form 13F-HR filing with the SEC under CIK 1766721.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 31.7#2,301
Quality
$378.0M5,089,611 sh - 30.0#2,378
Quality
$30.8M1,316,806 sh - 18.1#2,709
Quality
$25.6M1,555,664 sh - —
Quality
$11.3M568,919 sh - $9.1M1,018,018 sh
- —
Quality
$7.9M1,432,336 sh - —
Quality
$3.8M77,031 sh - —
Quality
$3.1M2,048,757 sh - —
Quality
$2.4M325,000 sh - —
Quality
$1.9M108,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BridgeBio Pharma, Inc.$BBIO | 31.7#2,301 | $378.0M | 5,089,611 |
 Syndax Pharmaceuticals Inc$SNDX | 30.0#2,378 | $30.8M | 1,316,806 |
 Monte Rosa Therapeutics, Inc.$GLUE | 18.1#2,709 | $25.6M | 1,555,664 |
 Bicara Therapeutics Inc.$BCAX | — | $11.3M | 568,919 |
 BridgeBio Oncology Therapeutics, Inc.$BBOT | — | $9.1M | 1,018,018 |
 COMPASS Pathways plc$CMPS | — | $7.9M | 1,432,336 |
 Scholar Rock Holding Corp$SRRK | — | $3.8M | 77,031 |
 Biomea Fusion, Inc.$BMEA | — | $3.1M | 2,048,757 |
 EUPRAXIA PHARMACEUTICALS INC.$EPRX | — | $2.4M | 325,000 |
 UroGen Pharma Ltd.$URGN | — | $1.9M | 108,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Aisling Capital Management LP's 13 positions.
Showing top 10 of 13 holdings.
Sector Allocation
Healthcare
$476.3M
Full Holdings — Aisling Capital Management LP (Q1 2026)
All 13 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BBIO | BridgeBio Pharma, Inc. | $378.0M | 79.3% | +0% | 31.7 |
| 2 | $SNDX | Syndax Pharmaceuticals Inc | $30.8M | 6.5% | +0% | 30 |
| 3 | $GLUE | Monte Rosa Therapeutics, Inc. | $25.6M | 5.4% | +6% | 18.1 |
| 4 | $BCAX | Bicara Therapeutics Inc. | $11.3M | 2.4% | +0% | — |
| 5 | $BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.1M | 1.9% | +80% | — |
| 6 | $CMPS | COMPASS Pathways plc | $7.9M | 1.7% | +20% | — |
| 7 | $SRRK | Scholar Rock Holding Corp | $3.8M | 0.8% | +0% | — |
| 8 | $BMEA | Biomea Fusion, Inc. | $3.1M | 0.7% | +0% | — |
| 9 | $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $2.4M | 0.5% | NEW | — |
| 10 | $URGN | UroGen Pharma Ltd. | $1.9M | 0.4% | +0% | — |
| 11 |  $ACRS | Aclaris Therapeutics, Inc. | $1.6M | 0.3% | +0% | 9.2 |
| 12 |  $MRKR | Marker Therapeutics, Inc. | $422,981 | 0.1% | +0% | — |
| 13 |  $OKUR | OnKure Therapeutics, Inc. | $366,833 | 0.1% | +0% | — |
New Positions (1)
$EPRX EUPRAXIA PHARMACEUTICALS INC.$2.4MExited Positions (1)
$CALC CalciMedica, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Aisling Capital Management LP including:
Track Aisling Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Aisling Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Aisling Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Aisling Capital Management LP (SEC CIK: 1766721), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Aisling Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.